Our data showed that hepatic glycogen content was significantly increased in NAFLD rats, whereas LGZG intervention markedly decreased hepatic glycogen (Fig. 4a, Table 2), which was consistent to the alteration of PTG and targeting proteins previously. The gene discussed is PPP1R3C; the disease is metabolic dysfunction-associated steatotic liver disease.